Using anti-GPVI antibody (anti-GPVI JAQ1), Pachel et al. [20] achieved a significant reduction in INF/AAR (infarct size per area at risk) after 30 minutes of ischemia and 24 hours of reperfusion, increase in myocardial microperfusion after ischemia/reperfusion (I/R), and reduction in the number of neutrophils in the myocardium. The gene discussed is GP6; the disease is ischemia.